For the active substances fluoxastrobin, pirimiphos-methyl, propamocarb and prothioconazole, as the Authority needs additional time to reach a conclusion on the risk, and in light of the remaining steps to be completed in each renewal procedure, the extension of the approval period for each of these active substances should be set at 19 months and 2 weeks.
Recital 42, Regulation (EU) 2025/787
In forcesince 24 Apr 2025